-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinical trial ...
CHICAGO--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the ...
CHICAGO--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback